Earnings review- Regeneron(REGN) Q2 2026
Muffett Investments
Earnings Watch · Stock Analysis Division
Earnings Review
30 July 2026
◆ Healthcare · Biotechnology
Regeneron Pharmaceuticals, Inc.
Report Period
Q2 FY2026
Reported: 2026-07-30
Headline
Strong Beat
→ Revenue $4.3B & Dupixent $6.0B Record
Key Metrics at a Glance
Total Revenue
$4.30B
+17.0% YoY (vs $4.21B est)
Non-GAAP EPS
$14.29
+11.0% YoY (vs $13.85 est)
Dupixent Global
$6.00B
+38.0% YoY Record (Sanofi)
EYLEA HD (US)
$596M
+52.0% YoY Conversion
Libtayo Global
$489M
+30.0% YoY Oncology
Financial Metrics — Detailed Breakdown
| Metric | Q2 FY2026 | Q2 FY2025 | YoY Change | Consensus Est. | vs. Estimate |
|---|---|---|---|---|---|
| Total Revenue | $4,300M | $3,675M | +17.0% | $4,210M | BEAT |
| Dupixent Global Net Sales | $6,000M | $4,348M | +38.0% | $5,750M | BEAT |
| EYLEA HD Net Sales (US) | $596M | $392M | +52.0% | $550M | BEAT |
| EYLEA Franchise Combined (US) | $1,008M | $1,145M | -12.0% | $1,020M | INLINE |
| Libtayo Global Net Sales | $489M | $376M | +30.0% | $460M | BEAT |
| Non-GAAP Diluted EPS | $14.29 | $12.87 | +11.0% | $13.85 | BEAT |
| GAAP Diluted EPS | $12.23 | $11.54 | +6.0% | — | N/A |
⚠ Management Highlights & Commercial Milestones
-
Dupixent Reaches All-Time Record $6.0B Global quarterly sales recorded by collaboration partner Sanofi surged +38% YoY to $6.0B, propelled by ongoing market expansion in asthma, eczema, and COPD indications.
-
Sanofi Development Balance Fully Repaid Management confirmed the Sanofi development balance was fully repaid at the end of Q2 FY26, unlocking higher collaboration net profit sharing starting in Q3 FY26.
📈 Stock Performance Context
Ticker
REGN
NASDAQ Listed
Sector
Biotechnology
Large Cap Bio
Q2 EPS Beat
+$0.44
$14.29 vs $13.85 est
Q2 Revenue Beat
+$90M
$4.30B vs $4.21B est
Regeneron's commercial portfolio continues to demonstrate exceptional durability, supported by EYLEA HD adoption and expanding collaboration profits.
Our Verdict
Strong Beat
Regeneron Pharmaceuticals delivered a standout Q2 FY2026 performance, generating $4.30B in total revenue (+17% YoY) and $14.29 Non-GAAP EPS (+11% YoY), beating consensus expectations across all major metrics. Growth was led by global mega-blockbuster Dupixent ($6.0B, +38% YoY) and rapid physician adoption of EYLEA HD ($596M, +52% YoY). The full repayment of the Sanofi development balance marks a major financial inflection that will boost net profit margins beginning in Q3 FY2026.
- Q2 Total Revenue of $4.30B surpassed consensus ($4.21B) with +17% top-line growth.
- Non-GAAP EPS of $14.29 beat estimates ($13.85), absorbing $0.99 of IPR&D impact.
- Dupixent global sales reached an all-time record of $6.0B (+38% YoY).
- Full repayment of Sanofi development balance unlocks structurally higher net profit sharing.
